RIPK1 and amyloidosis: Although a previous study had already reported elevated RIPK1 levels in AD patients (Ofengeim et al., 2017), since this disease is a secondary tauopathy underlying APP amyloidosis, it could not be confirmed that this increase in RIPK1 levels was a direct consequence of TAU hyperphosphorylation and aggregation.